Respironics Showcases Latest Technologies at Medtrade Spring; Building Upon Strong Fiscal Third Quarter Performance, Announces A
24 Aprile 2007 - 2:00PM
PR Newswire (US)
MURRYSVILLE, Pa., April 24 /PRNewswire-FirstCall/ -- Respironics,
Inc. (NASDAQ:RESP) will showcase its latest innovations for sleep
and home respiratory care at Medtrade Spring 2007. The
international tradeshow for the home healthcare industry kicks off
tomorrow at the Las Vegas Convention Center. Innovative sleep
therapy platforms, a new entry into in-home apneic screening, and
breakthroughs in mobile oxygen therapy systems are among the
offerings from Respironics. Adding to its family of technologically
advanced products, the Company also is premiering System One(TM) --
a new standard in sleep therapy that combines two of Respironics'
recent innovations. The Company stated that it is pleased to be
introducing these technologies to its previously strengthened
portfolio of products, including the recently introduced M Series
of devices and the OptiLife(TM) mask. These core products enabled
the Company to achieve global sleep therapy growth of 21% and
overall revenues, earnings and gross margins in line with previous
guidance during the Company's third fiscal quarter ended March 31,
2007. This performance was driven by 18% domestic and 31%
international sleep therapy growth. Respironics stated that it will
be providing a complete review of its fiscal 2007 third quarter
performance during its previously scheduled earnings call and
webcast on Thursday, April 26, 2007. Advances in Sleep Respironics
is very pleased to announce the introduction of A-Flex(TM), the
Company's newest breathing modality now being integrated into the
Company's REMstar(R) Auto CPAP device. Building on the proven
comfort of C- Flex(TM), A-Flex(TM) takes patient comfort to a new
level by matching pressure delivery to the patient's entire
breathing cycle. The A-Flex(TM) mode actually cycles with the
patient during the patient's inhalation phase in addition to
providing pressure relief during exhalation. System One(TM)
combines the innovative A-Flex(TM) breathing mode with the
Company's newest patient interface device, the OptiLife(TM) mask,
to provide the ultimate in patient therapy and comfort.
OptiLife(TM), the first in the My Life(TM) Series, was designed to
help patients get the most out of the revolutionary A-Flex(TM)
algorithm. The mask's flexible headgear design and chin support
provide a soft foundation for the seal and eliminate nasal
irritation, pressure, and pulling. It comes with pillow cushions in
four sizes to ensure an excellent seal for a wide range of
patients. At only 2.4 ounces, the OptiLife(TM) mask is one of the
lightest patient interface products available, and it is perfect
for side sleepers. John L. Miclot, President and Chief Executive
Officer of Respironics, commented, "We've had tremendous success
with the OptiLife(TM) mask since it was launched in January 2007.
We are excited about the combination of this innovative patient
interface device with our revolutionary A-Flex(TM) breathing mode.
We believe this combination, our new System One(TM), has the
capability to raise the standard of care in this marketplace. Our
new Obstructive Sleep Apnea (OSA) therapy systems are designed from
conception to deliver optimal patient care, and they are backed
with our renowned product support, promise programs, and business
solutions." Also being featured at Medtrade and introduced into the
U.S. market is the BiPAP(R) autoSV(TM) sleep therapy system, which
was recently granted 510(k) clearance from the U.S. Food and Drug
Administration (FDA). This highly advanced product was specifically
designed to provide noninvasive ventilatory support to treat
complicated sleep-disordered breathing patients suffering from OSA
and respiratory insufficiency caused by central and/or mixed apneas
and periodic breathing. It combines proven technologies that
recognize and respond to patients' changing pressure needs.
Rounding out the offerings in sleep is a brand new entry into
apneic screening with RUSleeping(TM) RTS, a same-day, objective,
in-home apneic event screener. The device was created to help get
people one step closer to diagnosis and treatment of OSA. Based
upon a patient's at-home overnight score, physicians can easily
tell if the patient is a likely candidate for a sleep study. About
the size of a pager, the device consists of a base unit, a
disposable nasal cannula, and AAA battery. It's easy to operate and
can be reused from patient-to-patient. Home Respiratory Care
Respironics is delivering on its promise of anticipating needs and
providing solutions to the home respiratory market with the launch
of the Freedom Series(TM) of oxygen therapy products. Respironics'
EverFlo(TM) is a five-liter, 31-pound stationary oxygen
concentrator designed to provide oxygen therapy to prescribed
patients while reducing associated costs such as maintenance, as
well as unscheduled patient calls and visits. The lighter weight
EverFlo(TM) concentrator uses less power, produces less heat and
noise, enables easy shipping and storage, and does not require a
filter replacement by the patient. Another cutting edge solution in
oxygen therapy in the Freedom Series, the EverGo(TM) Portable
Oxygen Concentrator, was designed for active individuals who need
help breathing. EverGo(TM) weighs less than 10 pounds, offers an
eight-hour battery life and 1050 milliliter per minute oxygen
capacity, and gives patients greater freedom so that they are not
limited by their devices. With products from the Freedom Series,
homecare providers are better equipped to control some of the costs
associated with oxygen therapy and make better use of reimbursement
rates. Ideal for air travel, EverGo(TM) has been approved for use
by the FAA and several commercial carriers: Alaska Air, American,
ATA, Delta, Frontier, Horizon, Midwest, Midwest Connect, Southwest,
and Sun Country. Emerson Acquisition The Company is also pleased to
announce that it has acquired substantially all of the operating
assets of the J. H. Emerson Company ("Emerson") for a purchase
price of approximately $23.0 million. Emerson is involved primarily
in the manufacture and distribution of the CoughAssist(R) device
that Respironics had previously distributed. The CoughAssist(R)
device provides secretion clearance to patients with Chronic
Obstructive Pulmonary Disease as well as certain other respiratory
ailments and conditions. CoughAssist(R) gives these patients an
effortless way to remove respiratory secretions that could
otherwise instigate an exacerbation of their illness. Emerson
achieved revenues for calendar year 2006 of approximately $8.0
million. Expanding the Portfolio "We are pleased to be expanding
our presence in the sleep and respiratory markets through both the
introduction of internally developed products as well as through
acquisitions such as Emerson. And, we are proud of our growing
portfolio of technologically advanced products and the
contributions our associates make worldwide to help us deliver
life-changing therapies to patients with sleep and respiratory
disorders," Mr. Miclot concluded. The Company stated that it will
not be changing its financial guidance or outlook based on this
announcement. About Respironics Respironics is a leading developer,
manufacturer and distributor of innovative products and programs
that serve the global sleep and respiratory markets. Focusing on
emerging market needs, the Company is committed to providing valued
solutions to help improve outcomes for patients, clinicians and
health care providers. Respironics markets its products in 131
countries and employs more than 4,900 associates worldwide. Further
information can be found on the Company's Web site:
http://www.respironics.com/ FORWARD-LOOKING STATEMENT This document
contains forward-looking statements, including statements relating
to, among other things, developments in the healthcare industry;
the success of the Company's marketing, sales, and promotion
programs; future sales, acceptance, and quality of the Company's
products and programs; the results of clinical trials; the timing
and success of new product introductions; new product development;
anticipated cost savings; FDA and other regulatory requirements,
enforcement actions, product recalls or related field actions;
future results from acquisitions and strategic investments; growth
rates in foreign markets; regulations and other factors affecting
operations and sales outside the United States; foreign currency
fluctuations; the effects of a major natural disaster, cyber-attack
or other catastrophic event that results in the destruction or
disruption of any critical business or information technology
systems; customer consolidation and concentration; increasing price
competition and other competitive factors in the manufacture,
distribution, and sale of products; interest rate fluctuations;
expiration of intellectual property rights; intellectual property
and related litigation; other litigation; future levels of earnings
and revenues; the number of equity awards granted to employees and
changes in the Company's stock price; and third party
reimbursement; all of which are subject to change. Actual results
may differ materially from those described in any forward-looking
statements. Additional information on potential factors that could
affect the Company's financial results are included in the reports
filed with the SEC, including the reports on Form 10-K, 10-Q and
8-K. DATASOURCE: Respironics, Inc. CONTACT: Dan Bevevino,
Respironics, Inc., Vice President & CFO, +1-724-387-5235, or
Joe Calabrese, General Contact, +1-212-827-3772, or Julie Tu,
Analyst Information, +1-212-827-3776, both of Financial Relations
Board Web site: http://www.respironics.com/
Copyright
Grafico Azioni Respironics (NASDAQ:RESP)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Respironics (NASDAQ:RESP)
Storico
Da Giu 2023 a Giu 2024